InvestorsHub Logo
Followers 59
Posts 18522
Boards Moderated 0
Alias Born 11/29/2006

Re: None

Tuesday, 01/10/2023 10:58:26 AM

Tuesday, January 10, 2023 10:58:26 AM

Post# of 343
From Vericel's preliminary results announced this morning

Announced FDA approval of NexoBrid(R) (anacaulase-bcdb) on December 28, 2022 for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns, with U.S. commercial availability expected in the second quarter of 2023

Also
Vericel is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 11, 2023. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MDWD News